Skip to main content

Table 2 Single-Agent mTOR Inhibitor Studies in Endometrial Cancer

From: New therapies for advanced, recurrent, and metastatic endometrial cancers

Agent

Patients

Prior Chemotherapy Regimens

Molecular Selection of Patients

Objective Response Rate

Other Activity

Temsirolimus [112]

29

None

No

24%

SD ≥ 8 weeks: 69%

25

1–2

No

4%

SD ≥ 8 weeks: 46%

Everolimus [113]

28

1–2

No

0%

SD: 43%

Everolimus [114]

44

1–2

No

9%

SD: 27%

Ridaforolimus IV [115]

45

1–2

No

11%

CBR: 29%

Ridaforolimus PO [116]

30

Adjuvant only

No

9%

SD: 52.9%

Ridaforolimus PO [117]

64

1–2

No

0%

SD: 35%

  1. IV intravenous, PO oral, SD stable disease, CBR clinical benefit rate